Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

Clinical activity was observed in metastatic melanoma (MM) patients treated with ipilimumab (IPI) combined with fotemustine (FTM) in the phase II NIBIT-M1 study. Peripheral blood mononuclear cells (PBMCs) and serum were collected from MM patients at pre- and at weeks 12 and 24 post-treatment. A comp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Maccalli, Cristina, Giannarelli, Diana, Capocefalo, Filippo, Pilla, Lorenzo, Fonsatti, Ester, Di Giacomo, Anna Maria, Parmiani, Giorgio, Maio, Michele
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4801454/
https://ncbi.nlm.nih.gov/pubmed/27057436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1071007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados